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ABSTRACT23
There is extensive literature on in vivo studies with cordycepin but these studies were generally24
conducted without validation of the various formulations, especially in terms of the solubility25
of cordycepin in the dosing vehicles used. Cordycepin is a promising drug candidate in multiple26
therapeutic areas and there is a growing interest in studies aimed at assessing the27
pharmacological activity of this compound in relevant animal disease models. It is likely that28
many reported in vivo studies used formulations in which cordycepin was incompletely soluble.29
This can potentially confound the interpretation of pharmacokinetics and efficacy results.30
Furthermore, the presence of particles in intravenously administered suspension can cause31
adverse effects and should be avoided. Here we present the results from our development of32
simple and readily applicable formulations of cordycepin based on quantitative solubility33
assessment. Homogeneous solutions of cordycepin were prepared in phosphate-buffered saline34
(PBS) at different pH levels, suitable as formulations for both intravenously and oral35
administration. For the purpose of high-dose oral administration we also developed propylene36
glycol (PPG)-based vehicles in which cordycepin is completely soluble. The stability of the37
newly developed formulations was also assessed, as well the feasibility of their sterilisation by38
filtration. Additionally, an HPLC-UV method for the determination of cordycepin in the39
formulations, which may also be useful for other purposes, was developed and validated. Our40
study could provide useful information for improvement of future preclinical and clinical41
studies involving cordycepin.42
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INTRODUCTION47
Cordycepin (3'-deoxyadenosine) is a nucleoside that differs from adenosine by the absence of48
the 3'-hydroxyl group. It is the main therapeutically active component in extracts of the insect49
fungus Cordyceps militaris, which is a widely used in traditional medicines of the Far East (1-50
3). The therapeutic potential of cordycepin has been recognised for a wide range of applications51
and was demonstrated in numerous studies (4). Proposed pharmacological activities of52
cordycepin include anti-microbial (4), anti-tumour (5-8), anti-mutagenic (9), anti-metastatic (1,53
10), anti-angiogenesis (11), anti-fungal (12), anti-diabetic (8, 13), anti-inflammatory (8, 13-17),54
anti-platelet aggregation (18), immunomodulatory (19, 20), hypoglycaemic (21) and anti-55
herpes (22) effects. The molecular mechanisms of action of cordycepin are not completely56
understood. However, like many natural products, cordycepin interacts with multiple57
biological processes, many of which remain to be investigated in detail (2).58
59
Based on diverse in vitro studies, in vivo preclinical research have been conducted for various60
indications including cancer (23, 24), cancer metastasis (25), vascular disorders (26),61
neurodegeneration (27, 28), fungal infection (12), osteoporosis (29, 30), osteogenesis (31),62
hyperlipidaemia (32), hyperglycaemia (21), viral infections (33), steroidogenesis (34), allergy63
(35), central nervous system disorders (36, 37), amongst others (38-40) (Table 1). Moreover,64
further studies are anticipated on the pharmacological modes of action and clinical efficacy of65
cordycepin.66
67
From the many in vivo experiments reported that involved cordycepin, it is noted that a68
substantial range of doses, and therefore a wide range of concentrations of cordycepin in69
different dosing vehicles, were used in these studies (Table 1). However, the solubility of70
cordycepin in water or other dosing vehicles used in these studies has not been reported as far71
as we can ascertain. Moreover, reports of such studies often do not indicate whether cordycepin72
formulations at the time of administration were actual homogeneous solutions or merely73
suspensions. If a formulation is administered orally or intraperitoneally as a suspension, factors74
such as dissolution and solubilisation could complicate interpretation of the results (41).75
Moreover, if a formulation for intravenous administration is a suspension rather than a solution,76
acute adverse effects can occur, especially if the suspension contains large particles. Such77
adverse effects can include embolism of blood vessels and inflammation (42-45).78
79
Therefore, in this study, simple and readily applicable formulations of cordycepin were80
developed based on quantitative solubility assessment. Homogeneous solutions of cordycepin81
were prepared in phosphate-buffered saline (PBS) at different pH levels, yielding formulations82
that can be administered both intravenously and orally. A propylene glycol (PPG)-based83
formulation for higher concentration oral cordycepin administration was also developed.84
Stability and sterilisation studies for the formulations developed were also carried out.85
86
MATERIALS AND METHODS87
Materials88
Cordycepin was purchased from Carbosynth Ltd (Berkshire, UK). Adenosine and Dulbecco’s89
phosphate buffered saline (PBS) were obtained from Sigma (Gillingham, UK). Water for90
injection was purchased from Gibco (Paisley, UK) and normal saline was from Baxter91
(Berkshire, UK). Costar Spin-X Centrifuge Tubes and propylene glycol were purchased from92
Fisher Scientific (Loughborough, UK). Sartorius Minisart syringe filters were obtained from93
Scientific Laboratory Supplies Ltd (Nottingham, UK). All solvents used in the study were94
HPLC grade or higher.95
96
Solubility assay97
To assess the solubility of cordycepin in water for injection, normal saline, pH 4.0 PBS, pH98
4.5 PBS and pH 5.0 PBS, saturated suspensions of cordycepin were prepared (15 mg of99
cordycepin per mL of solvent). The pH of the formulations in PBS were readjusted using HCl100
after dissolving cordycepin powder, to readjust the effect of solubilised cordycepin itself on101
the pH of the formulation. The test suspensions were contained in glass vials and were mixed102
using a vial roller, overnight at room temperature. The test suspensions were then filtered using103
Costar Spin-X Centrifuge Tubes (cellulose acetate, 0.22 μm pore size) by centrifugation at 104
2400 g for 5 min at room temperature (Heraeus Fresco 17 Centrifuge, Thermo Electron, MA,105
USA). The filtrate was analysed for the concentration of cordycepin. Solubility of cordyepin106
in PPG was assessed by preparing saturated suspensions at 20 mg of cordycepin per mL of107
solvent and sonicating for 15 min. The test suspensions were filtered using the method108
described above and the filtrates were analysed for cordycepin concentrations. The assay was109
conducted in quadruplicate.110
111
Formulation preparation112
Formulations of cordycepin were prepared based on PBS or PPG. For PBS-based formulations,113
the pH of PBS was adjusted to 4.0, 4.5 and 5.0 using NaOH or HCl prior to addition of114
cordycepin. PBS-based formulations were prepared by dissolving cordycepin in PBS at pH 4.0,115
4.5 and 5.0 at concentrations of 5.5, 4.5 and 3.0 mg/mL, respectively. The formulations were116
vortex-mixed and the pH of each formulation was then adjusted to its initial pH using HCl to117
account for the effect of solubilised cordycepin on the pH of the solution. The vortex-mix and118
pH re-adjustment steps were repeated until they resulted in clear solutions. For the PPG-based119
formulation, cordycepin was dissolved in PPG at a concentration of 13.0 mg/mL and the120
formulation was then sonicated in a water bath for 15 min. After confirming that the121
formulation was a clear solution, deionised-distilled water (DDW) was added to the122
formulation to give a final concentration of 10.0 mg/mL. This resulted in a PPG-based123
formulation with a composition of PPG:DDW = 77:23.124
125
Formulation stability test126
Formulations of cordycepin prepared as described above were tested for their stability at four127
different storage conditions: -80 °C, -20 °C, 4 °C and room temperature. Prepared formulations128
were aliquoted into 1.5 mL centrifuge tubes and were stored under different conditions. Three129
samples of each storage condition were withdrawn after 4 and 11 days, or 3, 8 and 12 weeks130
after preparation to assess the stability of the formulations.131
132
Filter sterilisation133
PBS-based formulations of cordycepin were filter-sterilised using Sartorius Minisart syringe134
filters (polyethersulfone, 0.2 μm pore size). Aliquots (700 μL) of the formulations prepared as 135
described above were filtered through the devices and air was purged using a 1 mL syringe.136
Concentrations of cordycepin in the formulations were measured before and after the filter137
sterilisation procedure. The evaluation was performed in quadruplicate.138
139
Analytical method140
Analysis of cordycepin concentrations in the samples was performed using a HPLC-UV system141
consisting of a Waters Alliance 2695 separations module equipped with a Waters 996142
photodiode array detector. The autosampler temperature was maintained at 10 °C and the143
column temperature was set at 40 °C. The stationary phase was a Capcell Pak C18 4.6 × 150144
mm, 3 μm particle size column (Shiseido, Tokyo, Japan), protected by a SecurityGuard 2 × 4 145
mm, 3 µm particle size column (Phenomenex, Macclesfield, UK). The mobile phase was an146
isocratic composition of acetonitrile:DDW at a ratio of 6:94 (v/v). The flow rate of the mobile147
phase was 0.8 mL/min and the chromatograms were monitored at a wavelength of 259 nm. The148
injection volume was 40 μL. 149
150
Sample preparation151
For HPLC-UV sample preparation, formulation samples were firstly diluted with DDW to yield152
1.0 mg/mL of cordycepin (dilution ratios were 18.2:81.8, 22.2:77.8, 33.3:66.7 and 10:90 for153
formulations of PBS pH 4.0, PBS pH 4.5, PBS pH 5.0 and PPG-based formulation,154
respectively). From these diluted samples, 10 μL was withdrawn and added to 980 μL of DDW 155
with 10 μL of internal standard stock solution (1.0 mg/mL adenosine in DDW). The samples 156
were then vortex-mixed and 100 μL aliquots were transferred to HPLC vials for analysis. 157
158
Calibration curve samples were prepared with working standard solutions of cordycepin (in159
DDW) at concentrations of 5, 10, 25, 50, 100, 250, 500 and 1000 μg/mL. DDW-based diluents 160
were prepared to match the composition of each formulation sample medium (0.187% PBS pH161
4.0, 0.227% PBS pH 4.5, 0.344% PBS pH 5.0 and 0.079% PPG). Samples were prepared by162
adding 20 μL of the cordycepin working standard solutions to 970 μL of the DDW-based 163
diluents with 10 μL of internal standard stock solution (1.0 mg/mL adenosine in DDW). The 164
resulting calibration curve points were 0.1, 0.2, 0.5, 1, 2, 5, 10 and 20 μg/mL. The samples 165
were then vortex-mixed and 100 μL aliquots were transferred to HPLC vials. 166
167
Validation of the analytical method168
Validation of the analytical method was performed for accuracy and precision. Accuracy was169
expressed as relative error (RE), which represents the bias from nominal concentrations.170
Precision was expressed as relative standard deviation (RSD), which represents the coefficient171
of variation at each concentration level (46, 47). Both accuracy and precision were assessed by172
intra-day (six replicates in one day) and inter-day (replicates on six different days) variability.173
The concentration levels of quality control (QC) samples were the lower limit of quantification174
(LLOQ, 0.1 μg/mL), low QC (LQC, 0.25 μg/mL), medium QC (MQC, 1.5 μg/mL) and high 175
QC (HQC, 15 μg/mL). The QC samples were prepared in the same manner as calibration curve 176
samples in each formulation sample medium.177
178
Statistical analysis179
All data were expressed as mean ± standard deviation (SD). Statistically significant differences180
between measurements in different media were assessed using the unpaired two-tailed t-test.181
The differences between measurements in one sample before and after sterilisation were182
assessed using the paired two-tailed t-test. Statistical significance was declared when p < 0.05.183
184
RESULTS185
Prior to formulation development, the maximal solubility of cordycepin in water for injection,186
normal saline, PBS at three different pH levels (4.0, 4.5 and 5.5) and PPG was assessed. The187
results are shown in Figure 1. The use of PBS at pH 4.0 and PPG resulted in significantly higher188
solubility of cordycepin compared to water or normal saline (both p < 0.001). Following the189
solubility results, formulations were developed in each medium at concentrations lower than190
the maximal solubility in the respective medium (Table 2). The PBS-based formulations were191
intended for intravenous and oral administration, while the PPG-based formulation was192
developed for higher dose oral administration. The achievable dose for each route of193
administration was calculated based on recommendation from a previous report (42, 43).194
195
The analytical method used for the stability assessment of the formulations was fully validated196
by intra-day and inter-day validation in order to evaluate the reliability of the method. The197
results in Table 3 show that the method has acceptable precision and accuracy at all QC levels198
tested. Representative chromatograms from the analytical method are shown in Figure 2.199
200
Stability of the formulations was assessed under four different storage conditions (-80 °C, -201
20 °C, 4 °C and room temperature) up to 3 months for PBS-based formulations and up to 3202
weeks for PPG-based formulations. The results in Table 4 show that all PBS-based203
formulations were stable at -80 °C, -20 °C and at room temperature for up to 3 months.204
Interestingly, crystallisation of cordycepin was observed in samples stored at 4 °C in PBS-205
based formulations. The rate of crystallisation differed with pH of the formulations, as206
crystallisation at pH 4.0 and at pH 4.5 in PBS was found after 6 days but at pH 5.0 in PBS only207
after 11 days. The PPG-based formulation was stable under all four storage conditions up to 3208
months and crystallisation was not observed in any of the samples.209
210
The feasibility of simple filter sterilisation of the PBS-based formulations was assessed by211
measuring the concentration of cordycepin before and after filtration. The results in Table 5212
show that there was no statistically significant loss during the filter sterilisation (p > 0.05).213
Therefore, filter sterilisation can be applied without compromising the concentration of the214
PBS-based formulations.215
216
DISCUSSION217
Knowledge of the maximal solubility of cordycepin in various dosing vehicles is essential218
information for the development of solution phase-based formulations. Some preclinical219
studies listed in Table 1 used concentrations that in fact exceed the maximal solubility of220
cordycepin in the respective dosing vehicles. Therefore, it is likely that the formulations used221
in these studies were in a suspension state. As previously mentioned, suspension-based222
formulations could complicate the interpretation of the results due to dissolution-related factors223
involved following oral or intraperitoneal administration. Intravenous administration of224
heterogeneous suspensions can also a cause adverse effects.225
226
PBS is an isotonic vehicle that causes minimal discomfort when administered intravenously or227
orally. The solubility of cordycepin in PBS was highest at pH 4.0, probably due to the fact that228
cordycepin is a weak base (pKa = 3.6, predicted by ACD/Labs, Toronto, Canada). Decreasing229
the pH further would likely result in even higher solubility. However, the recommended pH230
range for intravenous formulations is 4-9, and therefore the lowest pH tested in this work was231
4.0 (42).232
233
A PPG-based formulation was developed in order to enable higher doses of cordycepin to be234
delivered by the oral route. PPG is a widely-used and a well-tolerated dosing vehicle in235
preclinical studies. A previous study reported that oral administration of as much as 1000236
mg/kg/day of PPG for 90 days was tolerable in rats (48). The solubility of cordycepin in PPG237
was 2.7-fold higher than in pH 4.0 PBS (Figure 1). However, pure PPG as a dosing vehicle can238
present difficulties in practical use during preclinical experiments due to its high viscosity.239
Therefore PPG was diluted with DDW to produce the final formulation. As a result, our PPG-240
based formulation is composed of PPG:DDW = 77:23 at 10 mg/mL cordycepin and addition241
of water did not cause any precipitation of cordycepin in this formulation.242
243
The analytical method used in this study was developed based on a previous report where244
cordycepin was analysed in extracts of Cordyceps using HPLC-UV methods (49). However,245
this previously reported analytical method was limited by the fact that an internal standard was246
not used and validation results were not provided. Therefore, in the present study, we247
incorporated an internal standard to improve the precision and accuracy of the method and we248
also performed a full validation of the method (Table 3). This HPLC-UV method could provide249
useful information for future studies where concentrations of cordycepin are to be analysed in250
other formulations.251
252
Formulations intended for intravenous administration should not only be free of particles but253
should also be aseptic (42). In this study, filter sterilisation was tested for its feasibility, as it is254
one of the techniques that does not require heating of the formulation. One concern for filter255
sterilisation can be that the drug might have non-specific binding to the filter or the device. The256
results in our case showed that the PBS-based cordycepin formulations can be filter-sterilised257
without affecting the concentration of the formulations (Table 5).258
259
Surprisingly, and rather counterintuitively, we observed that a temperature of 4°C is the only260
storage condition to be avoided for PBS-based formulations. This is probably because the slow261
cooling process provided upon storage at 4°C resulted in crystallisation of cordycepin. It is262
often reasonable to assume that pharmaceutical formulations are more stable at lower263
temperatures (50). Moreover, when a label instructs to store a drug below a certain temperature264
(e.g. “store below 25 °C”), this usually means that storage in the fridge would provide stable265
conditions (51). However, the current study emphasises that storage of the formulations or266
dosage forms at lower temperature might in fact result in poorer stability from a physical point267
of view.268
269
270
CONCLUSION271
Herein, we report a study where simple and readily applicable formulations of cordycepin were272
developed and tested for their stability. An HPLC-UV method for quantification of cordycepin273
in the formulations was developed and validated. Additionally, the PBS-based formulations274
could be sterilised by filtration without loss of material. The PBS-based formulations were275
stable for up to 3 months at room temperature, -20°C and -80°C but not at 4°C, which suggests,276
rather counterintuitively, that storage of the formulations or dosage forms at lower temperature277
might in fact result in poorer physical stability. This study could provide useful information278
for future preclinical and clinical studies with cordycepin.279
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Table 1. List of preclinical studies conducted with cordycepin
Literature
(Reference) Dose
Dosing
volume Concentration Vehicle
Test
species ROA Indication
Won et al., 2009 (26) 10 mg/kg 2 mL/kg 5 mg/mL Water Rat p.o. Vascular disorder
Yoshikawa et al.,
2004 (23)
5, 15
mg/kg N.S. N.S. Water Mouse p.o. Cancer
Cheng et al., 2011
(27)
10, 20
mg/kg N.S. N.S. Water Mouse p.o.
Neuroprotective
activity
Rottenberg et al.,
2005 (38) 2 mg/kg N.S. N.S. N.S. Mouse i.p.
African
Trypanosomiasis
Sugar et al., 1998
(12) 1.5 mg/kg N.S. N.S. N.S. Mouse i.p. Antifungal activity
Wei et al., 2009 (39) 500
μmol/kg 
N.S. N.S. 2% Tween 80 Mouse p.o. Prodrug studies
Leu et al., 2011 (34) 20, 40mg/kg
1
mL/mouse 0.6, 1.2 mg/mL Saline Mouse i.p. Steroidogenesis
Tsai et al., 2010 (40) 10 mg/kg 1 mL/kg 10 mg/mL Saline Rat i.v. Pharmacokineticstudies
Sato et al., 2013 (25) 0.5, 5mg/kg N.S. N.S. DPBS Mouse i.p. Cancer metastasis
Zhang et al., 2015
(30)
22.2, 44.4,
88.9 mg/kg 10 mL 0.5, 1, 2 mg/mL Water Rat p.o. Osteoporosis
Sun et al., 2011 (32) 140 mg/kg N.S. N.S.
2.5%
carboxymethyl
cellulose
sodium
Hamster p.o. Hyperlipidaemia
Du et al., 2016 (33) 50 mg/kg N.S. N.S. N.S. Mouse i.p. Epstein-Barr virus
Tianzhu et al., 2015
(35)
20, 40
mg/kg N.S. N.S. N.S. Mouse p.o. Allergic asthma
Ma et al., 2015 (21) 8, 24, 72mg/kg N.S. N.S. Saline Mouse i.p. Hyperglycaemia
Cai et al., 2013 (36) 5, 10, 20mg/kg N.S. N.S. Water Mouse p.o. Cognitive function
Hu et al., 2013 (37) 2, 4 mg/kg N.S. N.S. Saline Rat N.S. Sleep regulation
Pan et al., 2015 (24) 20 mg/kg N.S. 0.1 % cordycepin PBS Mouse N.S. Cancer
Wang et al., 2015
(31)
1, 5, 10, 20
mg/kg N.S. N.S. N.S. Mouse i.p. Osteogenesis
Dou et al., 2016 (29) 10 mg/kg N.S. N.S. Water Mouse p.o. Osteoporosis
Yuan et al., 2016
(28)
1, 5, 10, 20
mg/kg N.S. N.S. Saline Rat i.v. Traumatic brain injury
N.S., not specified; p.o., oral; i.p., intraperitoneal; i.v., intravenous.
Table 2. Composition, concentration of developed formulations of cordycepin and their achievable dose in
various routes of administration
Composition
Cordycepin
concentration
(mg/mL)
Achievable dose (mg/kg)a
Intravenous
(5 mL/kg)
Oral
(20 mL/kg)
PBS-based
pH 4.0 PBS 5.5 27.5 110.0
pH 4.5 PBS 4.5 22.5 90.0
pH 5.0 PBS 3.0 15.0 60.0
PPG-based PPG:DDW = 77:23 10.0 - 200.0
a Achievable dose in each route of administration calculated according to recommendation from reference (42, 43).
Table 3. Intra-day and inter-day validation of the analytical method in each formulation sample medium (n
= 6)
Concentration levels
Intra-day Inter-day
Accuracy
(RE, %)
Precision
(RSD, %)
Accuracy
(RE, %)
Precision
(RSD, %)
Samples of pH 4.0 PBS
LLOQ (0.1 μg/mL) 10.45 3.45 1.76 6.89
LQC (0.25 μg/mL) 1.98 2.77 -2.29 4.40
MQC (1.5 μg/mL) 4.00 0.71 -1.11 6.15
HQC (15 μg/mL) 0.80 0.76   1.44 3.64 
Samples of pH 4.5 PBS
LLOQ (0.1 μg/mL) 8.95 2.85 6.54 4.01
LQC (0.25 μg/mL) 2.83 0.76 -0.53 3.48
MQC (1.5 μg/mL) 2.56 1.50 -2.69 3.43
HQC (15 μg/mL) 2.28 0.57   -1.46 2.44 
Samples of pH 5.0 PBS
LLOQ (0.1 μg/mL) 7.37 6.26 4.76 9.16
LQC (0.25 μg/mL) 4.36 2.49 0.55 5.65
MQC (1.5 μg/mL) 6.73 5.56 -1.13 6.34
HQC (15 μg/mL) 1.08 0.93   -2.42 4.70 
Samples of PPG:DDW = 77:23
LLOQ (0.1 μg/mL) 1.48 2.96 1.07 4.87
LQC (0.25 μg/mL) 2.43 2.98 2.22 3.14
MQC (1.5 μg/mL) -2.63 2.05 -1.81 2.03
HQC (15 μg/mL) 2.70 2.66    4.06 1.99  
Table 4. Stability of cordycepin formulation samples (mean ± SD, n = 3)
Formulation Storagecondition 4 days 11 days 3 weeks 2 months 3 months
pH 4.0 PBS
(5.5 mg/mL)
RT 98.8 ± 0.2 99.9 ± 1.8 97.7 ± 2.5 102.8 ± 3.7 104.8 ± 2.7
4°C 97.2 ± 2.0 88.8 ± 2.2 67.3 ± 3.8 72.2 ± 9.8 62.0 ± 8.0
-20°C 98.0 ± 0.4 97.5 ± 1.7 100.5 ± 4.7 99.4 ± 1.2 101.3 ± 3.4
-80°C 98.4 ± 0.8 98.2 ± 0.5 99.1 ± 9.2 99.6 ± 1.4 98.8 ± 8.4
pH 4.5 PBS
(4.5 mg/mL)
RT 93.9 ± 0.9 99.7 ± 1.2 101.9 ± 1.2 101.3 ± 0.4 97.4 ± 5.2
4°C 96.0 ± 3.8 72.0 ± 9.5 76.8 ± 11.1 41.7 ± 26.0 70.4 ± 18.4
-20°C 101.3 ± 4.8 98.7 ± 1.1 99.6 ± 1.2 94.0 ± 3.1 96.3 ± 4.5
-80°C 100.2 ± 7.8 99.9 ± 2.9 100.8 ± 1.1 109.8 ± 11.5 99.0 ± 6.2
pH 5.0 PBS
(3.0 mg/mL)
RT 96.9 ± 0.7 100.5 ± 2.7 102.8 ± 3.8 106.2 ± 2.5 106.8 ± 1.2
4°C 96.6 ± 1.4 87.4 ± 10.6 97.2 ± 11.8 85.2 ± 17.7 66.5 ± 4.2
-20°C 98.0 ± 2.8 99.2 ± 3.0 102.7 ± 5.3 110.4 ± 10.5 99.7 ± 2.2
-80°C 97.4 ± 0.9 99.5 ± 1.1 104.6 ± 0.3 108.3 ± 10.1 99.4 ± 7.0
PPG:DDW =
77:23
(10.0 mg/mL)
RT 102.1 ± 2.6 104.7 ± 1.6 106.0 ± 3.7 109.9 ± 1.0 104.0 ± 2.4
4°C 100.6 ± 0.2 104.1 ± 3.4 106.2 ± 0.5 105.5 ± 3.9 107.3 ± 0.8
-20°C 99.9 ± 1.5 104.9 ± 1.0 106.3 ± 0.7 102.4 ± 3.6 106.8 ± 2.0
-80°C 98.8 ± 1.3 103.8 ± 1.0 105.4 ± 2.4 104.9 ± 3.5 105.3 ± 0.6
RT, room temperature.
Table 5. Effects of filter sterilisation on concentrations of PBS-based cordycepin formulations (mean ± SD,
n = 4)
Formulation
Cordycepin concentration (mg/mL)
% remaining after
sterilisation
Before sterilisation After sterilisation
pH 4.0 PBS 5.52 ± 0.03 5.41 ± 0.20 98.09 ± 3.35
pH 4.5 PBS 4.45 ± 0.02 4.35 ± 0.11 97.91 ± 2.96
pH 5.0 PBS 3.02 ± 0.05 2.95 ± 0.06 97.77 ± 1.85
LEGENDS TO FIGURES
Figure 1. Solubility of cordycepin in different media (mean ± SD, n = 4). ***, p<0.001
compared to water and saline by unpaired two-tailed t-test.
Figure 2. Representative chromatograms of cordycepin and internal standard (IS, adenosine)
from HPLC-UV analysis. A, baseline chromatogram observed after injection of 100% DDW;
B, calibration curve sample spiked with 10 ug/mL cordycepin and IS into pH 4.5 PBS-based
medium; C, MQC sample in PPG-based medium; D, stability test sample of pH 4.0 PBS
formulation after 3 weeks of storage at 4°C.


